ZA868943B - Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process - Google Patents

Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process

Info

Publication number
ZA868943B
ZA868943B ZA868943A ZA868943A ZA868943B ZA 868943 B ZA868943 B ZA 868943B ZA 868943 A ZA868943 A ZA 868943A ZA 868943 A ZA868943 A ZA 868943A ZA 868943 B ZA868943 B ZA 868943B
Authority
ZA
South Africa
Prior art keywords
fusion proteins
new
preparation
carrying
derivs
Prior art date
Application number
ZA868943A
Other languages
English (en)
Inventor
Paul Habermann
Friedrich Wengenmayer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA868943B publication Critical patent/ZA868943B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA868943A 1985-11-27 1986-11-26 Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process ZA868943B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853541856 DE3541856A1 (de) 1985-11-27 1985-11-27 Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens

Publications (1)

Publication Number Publication Date
ZA868943B true ZA868943B (en) 1987-07-29

Family

ID=6286938

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA868943A ZA868943B (en) 1985-11-27 1986-11-26 Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process

Country Status (17)

Country Link
EP (3) EP0227938B1 (xx)
JP (1) JP2566933B2 (xx)
KR (1) KR950000300B1 (xx)
AT (2) ATE127841T1 (xx)
AU (1) AU595262B2 (xx)
CA (1) CA1341203C (xx)
DE (4) DE3541856A1 (xx)
DK (2) DK172064B1 (xx)
ES (3) ES2077747T3 (xx)
FI (1) FI93471C (xx)
GR (1) GR3005042T3 (xx)
HU (1) HU203579B (xx)
IE (1) IE59488B1 (xx)
IL (1) IL80755A0 (xx)
NO (1) NO176481C (xx)
PT (1) PT83813B (xx)
ZA (1) ZA868943B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125021A (en) * 1955-11-14 1964-03-17 Smooth
EP0168342B1 (de) * 1984-06-14 1991-07-03 Ciba-Geigy Ag Verfahren zur Herstellung von Thrombin-Inhibitoren
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
DE3835815A1 (de) * 1988-10-21 1990-04-26 Hoechst Ag Neue isohirudine
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
CU22222A1 (es) * 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (de) * 1989-12-22 1991-06-27 Basf Ag Verfahren zur herstellung von hirudin
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE4140381A1 (de) * 1991-12-07 1993-06-09 Hoechst Ag, 6230 Frankfurt, De Neue synthetische isohirudine mit verbesserter stabilitaet
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
ES2218622T3 (es) 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
CA1341417C (fr) * 1984-03-27 2003-01-21 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
US4865974A (en) * 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals

Also Published As

Publication number Publication date
DK52292A (da) 1992-04-21
DE3684892D1 (de) 1992-05-21
EP0468539A1 (de) 1992-01-29
ES2077747T3 (es) 1995-12-01
IE59488B1 (en) 1994-03-09
AU6569386A (en) 1987-06-04
DE3541856A1 (de) 1987-06-04
ATE122397T1 (de) 1995-05-15
NO176481C (no) 1995-04-12
FI864798A (fi) 1987-05-28
DE3650322D1 (de) 1995-06-14
FI93471B (fi) 1994-12-30
DK172210B1 (da) 1998-01-05
FI864798A0 (fi) 1986-11-25
IL80755A0 (en) 1987-02-27
DK568586D0 (da) 1986-11-26
CA1341203C (en) 2001-03-13
NO176481B (no) 1995-01-02
ATE127841T1 (de) 1995-09-15
NO864759D0 (no) 1986-11-26
KR870005098A (ko) 1987-06-04
JP2566933B2 (ja) 1996-12-25
HU203579B (en) 1991-08-28
KR950000300B1 (ko) 1995-01-13
DK172064B1 (da) 1997-10-06
EP0227938A3 (en) 1988-11-23
ES2032378T3 (es) 1993-02-16
DE3650396D1 (de) 1995-10-19
FI93471C (fi) 1995-04-10
GR3005042T3 (xx) 1993-05-24
HUT43642A (en) 1987-11-30
DK52292D0 (da) 1992-04-21
EP0468539B1 (de) 1995-09-13
DK568586A (da) 1987-05-28
EP0227938A2 (de) 1987-07-08
PT83813A (de) 1986-12-01
JPS62143696A (ja) 1987-06-26
EP0464867A1 (de) 1992-01-08
ES2073081T3 (es) 1995-08-01
EP0227938B1 (de) 1992-04-15
EP0464867B1 (de) 1995-05-10
IE863119L (en) 1987-05-27
AU595262B2 (en) 1990-03-29
PT83813B (pt) 1989-06-30

Similar Documents

Publication Publication Date Title
IL80755A0 (en) Eukaryotic fusion proteins,the preparation and use thereof,and means for carrying out the process
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
FR2681786B1 (xx)
ES8402351A1 (es) Procedimiento para producir interferon inmune humano.
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
ES8306324A1 (es) "proceso para la produccion microbiana de interferon fibroblasto humano".
ES8801517A1 (es) Un metodo para producir proteina tensioactiva alveolar
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
ES8704207A1 (es) Procedimiento para preparar una molecula de adn
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
EP0165759A3 (en) Mammalian promotors useful in yeast expression